Drug Patent Watch

OCTOBER 12, 2021

This paper was originally published by Md. Imtiaz Hasan et al in Journal of Biosciences and Medicines under a Creative Commons Attribution 4.0 International License Abstract Development of generic drug product…. The post Development of Generic Drug Products by Pharmaceutical Industries Considering Regulatory Aspects: A Review appeared first on DrugPatentWatch - Make Better Decisions.

Production 105

Production Pharmaceuticals Licensing Licensing 105

Drug Discovery Today

OCTOBER 13, 2021

Construction of No.1 Birmingham Health Innovation Campus (BHIC) in Selly Oak is underway, marking a major milestone for the region’s rapidly growing life sciences sector.

Science 100

Science 100

Drug Channels

OCTOBER 12, 2021

Payers have long sought to disrupt the buy-and-bill channel. Coming out of the pandemic (maybe?), specialty pharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. Check out the latest 2021 data below. The battle for the specialty patient pits hospitals against insurers—and their respective specialty pharmacies.

Specialty Pharmacies 97

Specialty Pharmacies Pharmacy Hospitals Pharmaceuticals 97

The Pharma Data

OCTOBER 14, 2021

MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccination Data from this analysis also suggest that approximately 40 percent of people with MS treated with anti-CD20 and S1P disease-modifying therapies (DMT) mount an antibody response to the COVID-19 vaccine Collaborative MS PATHS network enabled rapid collection of data in the COVID-19 environment.

Vaccine 52

Vaccine Therapies Immune Response Disease 52

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Treatment

Drug Patent Watch

OCTOBER 15, 2021

This chart shows the pharmaceutical companies with the most lotion dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most lotion dosed drugs…. The post Which pharmaceutical companies have the most lotion dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

Drug Channels

OCTOBER 15, 2021

Today’s guest post comes from Jayne Hornung, Chief Clinical Officer at MMIT. Jayne discusses changes in the life science and specialty pharmacy industries since the COVID-19 pandemic began. She highlights three key trends that pharma companies, plan sponsors, and others will consider as we head to the upcoming Asembia Specialty Pharmacy Summit (October 26 to 29 in Las Vegas).

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Pharma Companies Science 75

The Pharma Data

OCTOBER 14, 2021

COBRA study subgroups results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Non-interventional study analysis found no evidence of safety concerns with infants of mothers with multiple sclerosis (MS) who were exposed to glatiramer acetate (GA) treatment during pregnancy and breastfeeding Maternal pregnancy and breastfeeding exposure to GA in this study did not adversely affect offspring with regard to hospitalisations and ant

Treatment 52

Treatment Pharmaceuticals Hospitals Production 52

Drug Patent Watch

OCTOBER 15, 2021

Annual Drug Patent Expirations for NEXLIZET Nexlizet is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are six patents protecting this drug. NEXLIZET drug…. The post New patent for Esperion Theraps drug NEXLIZET appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The ChEMBL-og

OCTOBER 13, 2021

If you use ChEMBL via the interface and are interested in programmatic approaches then join our webinar on November 10th @ 15:30 to find out more ! In this webinar, we'll provide an overview of the ChEMBL and UniChem APIs and work through some common examples. In the meantime, don’t forget that we have further documentation on our web services as well as a recent ChEMBL webinar, a Blog and series of FAQs.

52

52

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Clinical Trials

Crown Bioscience

OCTOBER 12, 2021

In this post, we discuss modern flow cytometry as a game-changer for cell functional assays, immune monitoring, and function-based screening of drug candidates to support and accelerate your biomarker strategy and translational programs.

Drugs 52

Drugs 52

The Pharma Data

OCTOBER 14, 2021

ALITHIOS Phase IIIb open-label extension study data based on ~3.5 years of exposure demonstrated that mean immunoglobulin G (IgG) levels in patients treated with Kesimpta remained stable, and there was no apparent association between decreased IgG levels and the risk of serious infections 1 ALITHIOS Phase IIIb open-label extension study data also showed mean immunoglobulin M (IgM) levels declined over time but remained within the reference range for the majority of patients.

Treatment 52

Treatment Therapies Science Pharmaceuticals 52

Drug Patent Watch

OCTOBER 15, 2021

Annual Drug Patent Expirations for INJECTAFER Injectafer is a drug marketed by Am Regent and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Am Regent drug INJECTAFER appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 14, 2021

Annual Drug Patent Expirations for ORLADEYO Orladeyo is a drug marketed by Biocryst and is included in one NDA. There are four patents protecting this drug. This drug has forty…. The post New patent for Biocryst drug ORLADEYO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Clinical Trials

Drug Patent Watch

OCTOBER 14, 2021

This chart shows the pharmaceutical companies with the most film dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most film dosed drugs…. The post Which pharmaceutical companies have the most film dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Drugs 52

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s disease (AD). This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as

Therapies 52

Therapies Disease FDA Trials 52

The Pharma Data

OCTOBER 14, 2021

Short duration infusion of Gazyvaro® (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Results from the phase IV GAZELLE study showed no new safety signals with the shorter infusion of Gazyvaro Shorter infusions could be more convenient for patients by reducing time in hospital and easing pressure on healthcare systems [1].

Small Molecule 52

Small Molecule Treatment Hospitals Disease 52

Drug Patent Watch

OCTOBER 13, 2021

This chart shows the drugs with the most patents in Portugal. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Portugal? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Clinical Trials

The Pharma Data

OCTOBER 12, 2021

THE POWER OF YOU CAMPAIGN ADVOCATES FOR AWARENESS AND EMPOWERS CONFIDENCE. Allergan Aesthetics, an AbbVie company (NYSE ABBV), is continuing its commitment to bone health, mindfulness, restoration, and exploration in support of bone cancer mindfulness month. For the month of October and into 2022, Allergan Aesthetics, The Power of You crusade will protest off a new series of enterprise and hookups to support associations creating a measurable impact in the fight against bone cancer.

Production 52

Production Drugs 52

The Pharma Data

OCTOBER 12, 2021

The Award recognizes the research that has the highest translational potential Translational medicine is an interdisciplinary branch in the biomedical field that aims to combine benchside, bedside and community to promote enhancement in prevention, diagnosis, and treatment. Boehringer Ingelheim, a global leader in animal health, has awarded its first biennial Translational Medicine Award during the North American Veterinary Regenerative Medicine Association (NAVRMA 2021) conference in Colorado,

Research Laboratories 52

Research Laboratories Laboratories Therapies Production 52

The Pharma Data

OCTOBER 12, 2021

Trial met primary endpoint. AZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19. Positive high- position results from the Paraphernalia Phase III COVID-19 treatment trial showed AstraZeneca’s AZD7442, a long amusement antibody (LAAB) combination, achieved a statistically significant reduction in severe COVID-19 or death compared to placebo innon-hospitalised cases with mild-to-moderate characteristic COVID-19.

Trials 52

Trials Treatment Virus Disease 52

Drug Patent Watch

OCTOBER 12, 2021

This chart shows the drugs with the most patents in Spain. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

Pharmaceuticals 52

Pharmaceuticals Drugs 52

Drug Patent Watch

OCTOBER 12, 2021

Annual Drug Patent Expirations for EPCLUSA Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from one supplier. There are fourteen…. The post New patent for Gilead Sciences drug EPCLUSA appeared first on DrugPatentWatch - Make Better Decisions.

Science 52

Science Drugs Marketing 52

Drug Patent Watch

OCTOBER 12, 2021

Annual Drug Patent Expirations for BREO+ELLIPTA Breo Ellipta is a drug marketed by Glaxo Grp Ltd and is included in one NDA. It is available from two suppliers. There are…. The post New patent for Glaxo Grp drug BREO ELLIPTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 12, 2021

Annual Drug Patent Expirations for VASCEPA Vascepa is a drug marketed by Amarin Pharms and is included in one NDA. It is available from two suppliers. There are sixty-three patents…. The post New patent for Amarin Pharms drug VASCEPA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 12, 2021

Annual Drug Patent Expirations for TALICIA Talicia is a drug marketed by Redhill and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent for Redhill drug TALICIA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Drug Patent Watch

OCTOBER 12, 2021

Annual Drug Patent Expirations for LEVOTHYROXINE+SODIUM Levothyroxine Sodium is a drug marketed by Teva Pharms Usa Inc, Dr Reddys, Fresenius Kabi Usa, Maia Pharms Inc, Par Sterile Products, Piramal Critical,…. The post New patent for Fresenius Kabi drug LEVOTHYROXINE SODIUM appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Production Marketing 52

Drug Patent Watch

OCTOBER 12, 2021

Annual Drug Patent Expirations for VENCLEXTA Venclexta is a drug marketed by Abbvie Inc and is included in one NDA. It is available from one supplier. There are six patents…. The post New patent for Abbvie Inc drug VENCLEXTA appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52